Shareholders to Vote on Highly Dilutive Financing and Acquisition Critical for Company Survival

summarizeSummary

Lifeward Ltd. is seeking shareholder approval for a highly dilutive financing package and acquisition of Oratech Pharma, Inc., which is crucial for the company's survival but will result in approximately 88% dilution for current shareholders and establish Oramed as a controlling entity.

check_boxKey Events

• Shareholder Vote on Dilutive Financing and Acquisition

  Shareholders will vote on the issuance of approximately 131.3 million ordinary shares, pre-funded warrants, convertible notes, and warrants to Oramed and other investors as part of the Oratech acquisition and related financing.

• Extreme Shareholder Dilution

  The proposed transactions are expected to result in approximately 88% dilution for existing shareholders, significantly altering their ownership stake in the company.

• Financing Critical for Company Survival

  Lifeward Ltd. explicitly states that approval of this financing is necessary to repay a $3.0 million secured promissory note and to continue operations beyond Q1 2026, indicating a critical financial need.

• Discounted Pricing and Change of Control

  The securities are being issued at a price below Nasdaq's 'minimum price' rules, with a conversion/exercise price of $0.45 per share, and Oramed is expected to become a controlling shareholder with up to 49.99% of voting power.

auto_awesomeAnalysis

This preliminary proxy statement details an Extraordinary General Meeting where shareholders will vote on a series of proposals critical for Lifeward Ltd.'s continued operations, following previous disclosures on January 13 and January 28, 2026, regarding a strategic shift and dilutive share issuances. The most significant proposal involves approving the issuance of shares, pre-funded warrants, convertible notes, and warrants to Oramed Pharmaceuticals Inc. and other investors. This transaction is projected to result in approximately 88% dilution for existing shareholders and will establish Oramed as a controlling shareholder. The company explicitly states that approval is necessary to repay a $3.0 million secured promissory note maturing in May 2026 and to fund operations beyond the first quarter of 2026, highlighting a distressed financial situation. The terms of the financing, including a conversion/exercise price of $0.45 per share compared to the current stock price of $0.66, represent a substantial discount. Additionally, shareholders will vote on a significant equity grant to CEO Mark Grant, further increasing potential dilution.